58
Participants
Start Date
November 14, 2018
Primary Completion Date
November 2, 2021
Study Completion Date
November 2, 2021
AK002
AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Mount Sinai, New York
University of Pennsylvania, Philadelphia
NIH, Bethesda
University of North Carolina - Chapel Hill, Chapel Hill
Advanced Research Institute, New Port Richey
Vanderbilt University, Nashville
ClinSearch, Chattanooga
Cincinnati Children's Hospital, Cincinnati
University of Iowa, Iowa City
Mayo Clinic, Rochester
Northwestern, Chicago
Avant Research Associates, Austin
University of Utah, Salt Lake City
Phoenician Centers for Research and Innovation, Phoenix
Mayo Clinic Arizona, Scottsdale
Ventura Clinical Trials, Ventura
Tufts Medical Center, Boston
Lead Sponsor
Allakos Inc.
INDUSTRY